{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals Hits New 52-Week High of $55.95
Supernus Pharmaceuticals, Inc. achieved a new 52-week high of USD 55.95 on October 29, 2025, reflecting its strong performance in the pharmaceuticals sector. The company has seen a significant stock price increase over the past year and maintains a solid financial position with low debt reliance.
Supernus Pharmaceuticals Hits New 52-Week High of $53.28
Supernus Pharmaceuticals, Inc. has achieved a new 52-week high, reflecting its strong performance in the pharmaceuticals and biotechnology sector. The company has seen significant growth over the past year, with a notable increase in its stock price and a solid financial position characterized by a low debt-to-equity ratio.
Is Supernus Pharmaceuticals, Inc. overvalued or undervalued?
As of October 17, 2025, Supernus Pharmaceuticals, Inc. is considered overvalued with a P/E ratio of 29 and an EV to EBITDA of 9.02, despite a strong year-to-date return of 38.74%, especially when compared to lower valuation metrics of competitors like PTC Therapeutics and Harmony Biosciences.
Supernus Pharmaceuticals, Inc. Experiences Valuation Adjustment Amid Strong Market Performance
Supernus Pharmaceuticals, Inc. has adjusted its valuation, reflecting shifts in financial metrics within the pharmaceuticals sector. The company exhibits a P/E ratio of 29 and a return on capital employed of 13.09%. Year-to-date, its stock has outperformed the S&P 500, indicating a strong market position.
Is Supernus Pharmaceuticals, Inc. overvalued or undervalued?
As of October 17, 2025, Supernus Pharmaceuticals, Inc. is considered overvalued with a P/E ratio of 29 and a valuation grade shift from very attractive to expensive, despite a strong year-to-date return of 38.74% that outpaces the S&P 500's 13.30%, although its longer-term performance lags behind the market.
Is Supernus Pharmaceuticals, Inc. overvalued or undervalued?
As of October 17, 2025, Supernus Pharmaceuticals, Inc. is considered overvalued due to a high P/E ratio of 29 compared to its peers and strong performance returns, despite indicating potential unsustainability at these valuation levels.
Supernus Pharmaceuticals Hits New 52-Week High of $49.66
Supernus Pharmaceuticals, Inc. has achieved a new 52-week high, reflecting its strong performance in the pharmaceuticals and biotechnology sector. The company has seen significant growth over the past year, with a solid financial position characterized by a low debt-to-equity ratio and a positive return on equity.
Supernus Pharmaceuticals Hits New 52-Week High of $48.00
Supernus Pharmaceuticals, Inc. achieved a new 52-week high of USD 48.00 on September 26, 2025, reflecting strong performance in the pharmaceuticals sector with a one-year growth of 79.57%. The company, with a market cap of USD 2,569 million, shows solid financial health and minimal debt.
Supernus Pharmaceuticals Hits New 52-Week High of $47.65
Supernus Pharmaceuticals, Inc. achieved a new 52-week high of USD 47.65 on September 23, 2025, reflecting a strong one-year performance of 78.81%. With a market capitalization of USD 2,569 million, the company demonstrates solid financial metrics, including a P/E ratio of 29.00 and a return on equity of 6.51%.
Supernus Pharmaceuticals Hits New 52-Week High of $47.07
Supernus Pharmaceuticals, Inc. achieved a new 52-week high of USD 47.07 on September 22, 2025, reflecting strong growth in the pharmaceuticals sector. The company has seen a 79.38% increase in stock price over the past year, significantly outperforming the S&P 500, and maintains a solid financial position.
Is Supernus Pharmaceuticals, Inc. technically bullish or bearish?
As of August 18, 2025, Supernus Pharmaceuticals, Inc. shows a strong bullish trend supported by positive technical indicators, outperforming the S&P 500 with a 7.30% return over the past month and 44.88% over the past year.
Is Supernus Pharmaceuticals, Inc. overvalued or undervalued?
As of August 22, 2025, Supernus Pharmaceuticals, Inc. is considered overvalued with a P/E ratio of 29, significantly higher than its peers and the industry average, despite strong recent returns.
Is Supernus Pharmaceuticals, Inc. overvalued or undervalued?
As of June 12, 2025, Supernus Pharmaceuticals is fairly valued with a P/E ratio of 29 and strong growth potential, despite slightly trailing its peers and the S&P 500 in stock performance over the past year.
Is Supernus Pharmaceuticals, Inc. technically bullish or bearish?
As of June 17, 2025, Supernus Pharmaceuticals, Inc. exhibits a neutral trend with mixed signals from various indicators, showing mild bullishness on the weekly MACD and KST, but bearishness on the daily moving averages and weekly Bollinger Bands.
Who are in the management team of Supernus Pharmaceuticals, Inc.?
As of March 2022, the management team of Supernus Pharmaceuticals, Inc. includes Independent Chairman Mr. Charles Newhall, President and CEO Mr. Jack Khattar, and Independent Directors Dr. Carrolee Barlow, Dr. Georges Gemayel, Mr. Frederick Hudson, and Dr. John Siebert. They oversee the company's strategic direction and operations.
What does Supernus Pharmaceuticals, Inc. do?
Supernus Pharmaceuticals, Inc. is a micro-cap pharmaceutical company focused on developing treatments for central nervous system diseases, with recent net sales of $150 million and a net profit of -$12 million. The company has a market cap of approximately $1.81 billion.
How big is Supernus Pharmaceuticals, Inc.?
As of Jun 18, Supernus Pharmaceuticals, Inc. has a market capitalization of $1.81 billion, with net sales of $668 million and a net profit of $62 million over the latest four quarters.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
